Introduction {#Sec1}
============

Homozygous or compound heterozygous germline mutations in the *ATM* gene cause the autosomal recessive disorder ataxia-telangiectasia (A-T). This progressive neurological childhood disease is characterized by cerebellar degeneration, immunological defects, extreme sensitivity for ionising radiation and increased risk for cancers, particularly lymphomas \[[@CR1]\]. *ATM* mutations identified in A-T families can be classified in three categories; truncating mutations, mutations that lead to some expression of mutant protein that lacks kinase activity and missense mutations with reduced kinase activity (<http://chromium.liacs.nk/lovd/>).

Heterozygous pathogenic *ATM* mutation carriers, ∼0.5--1% of the general population, do not display the symptoms observed in A-T patients. Several epidemiological studies have consistently shown elevated rates of breast cancer among female blood relatives of patients with A-T \[[@CR2], [@CR3]\]. Thompson et al. have shown that the overall relative risk in carriers was 2.23 \[95% confidence interval (CI) 1.16--4.28\] compared to the general population and 4.95 (95% CI 1.9--12.9) in those younger that age 50. A large review showed that *ATM* mutations are more frequent in breast cancer patients selected on the basis of a family history of breast cancer than in unselected patients \[[@CR4]\]. Besides pathogenic *ATM* mutations, a large number of *ATM* variants (common polymorphisms and unclassified variants) have been described, which were found in cancer patients as well as in the general population. It has been hypothesized that the cancer risk among *ATM* heterozygotes might be related to mutation type, suggesting that particularly missense mutations are associated with an increased risk \[[@CR5], [@CR6]\]. However, two recent studies by Thompson et al. and Renwick et al. showed that pathogenic *ATM* mutations that cause A-T are breast cancer susceptibility alleles \[[@CR2], [@CR7]\]. This argues against the hypothesis that missense rather that truncating are associated with breast cancer.

Women with breast cancer have in general a three to fourfold increased risk of developing a new primary cancer in the opposite breast \[[@CR8]\]. The contralateral breast cancer (CBC) risk might be explained by the same genetic and hormonal factors that caused the first breast cancer. Treatment related factors, e.g. radiotherapy for primary breast cancer, may also contribute to the development of cancer in the contralateral breast \[[@CR9]\] (our own data, manuscript under review).

To evaluate whether germline *ATM* missense variants are significantly associated with CBC risk (results regarding ATM truncating mutations are reported elsewhere) and whether treatment modifies this risk, we conducted a case-control study in which we assessed the *ATM* missense mutation spectrum and frequency in women who developed their first breast cancer before age 50, with and without a second primary breast cancer.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

The consecutive breast cancer patients included in this study were all selected from the hospital tumour registries of The Netherlands Cancer Institute, Amsterdam (NKI-AVL) or The Dr. Daniel den Hoed Cancer Center/Erasmus Medical Center, Rotterdam (DDHK). Of all patients that were invited to participate we achieved an 80% response rate. The breast cancer patients were included if their (first) breast cancer was diagnosed before age 50 (*n* = 443). For CBC we required an interval of at least 1 year (*n* = 247). The unilateral breast cancer patients (UBC) patients all had to be disease-free (of a second breast cancer) for at least 5 years. The first 57 CBC patients were individually age-matched (1:3) to UBC controls. All patients had invasive breast carcinoma and were treated with surgery. Of the CBC patients 169 did and 78 did not receive radiotherapy treatment for their primary breast tumour. Average age at diagnosis for the first breast cancer in the RT group was 41.2/41.3 years (mean/median) and the non-exposed group 42.0/43.2 years (mean/median). Detailed treatment data, disease and patient characteristics were obtained from medical records and risk factor questionnaires (data not shown) \[[@CR10], [@CR11]\]. Patients were asked to donate a 20 ml blood sample or permission for use of paraffin-embedded tissue blocks and patients gave their written informed consent for mutation analysis. This study received approval of the Medical Ethical Committees of NKI-AVL and DDHK.

Genomic DNA isolation {#Sec4}
---------------------

Genomic DNA was either isolated from peripheral blood lymphocytes with DNAzol (Invitrogen, Breda, The Netherlands) methods according to the manufacturer's instructions, or from three 10-μm paraffin embedded normal tissue slides according to standard protocols \[[@CR12]\]. For histopathological examination we used a hematoxylin-eosin stained slide.

Mutation analysis {#Sec5}
-----------------

The complete *ATM* Open Reading Frame (ORF) was analysed, each exon (exon 4-65) and all intron-exon boundaries were screened for germline mutations using Denaturing Gradient Gel Electrophoresis (DGGE) identifying ∼90% of all *ATM* mutations and polymorphisms (details from the author upon request). All aberrations were confirmed with genomic sequence analysis, performed using the ABI PRISM BigDyeTerminator Cycle Sequencing Ready Reaction Kit Version 3.1 (Applied Biosystems, Nieuwerkerk a/d yssel, The Netherlands). Sequencing products were analysed with the ABI PRISM 3700 DNA Analyzer and corresponding software.

Statistical analysis {#Sec6}
--------------------

Statistical analyses were performed using standard methods for analysis of case-control studies \[[@CR13]\]. We compared the mutation frequency between UBC and CBC and between CBC cases previously treated with RT and cases not-treated with RT. Odds ratios (ORs) and 95% CI were calculated to evaluate the association between mutation carriers status and breast cancer risk. We have used the Mann--Whitney test to determine whether the difference between the intervals between the two breast cancers of the CBC patients was significant. All analyses were performed using SPSS 12.0 (SPSS Inc., Chicago, IL, USA).

Results and discussion {#Sec7}
======================

ATM germline mutations {#Sec8}
----------------------

In the present study, we have used the DGGE method to screen the complete *ATM* ORF to obtain insight in the *ATM* missense mutation spectrum in (contralateral) breast cancer patients. With DGGE we were able to confirm all the previously identified truncating mutations. A subset of the CBC patients described in this study had been screened in the past for *ATM* truncating mutations with the Protein Truncating Test, revealing seven *ATM* truncating mutations (including a non-sense mutation and small insertions and deletions; generating stop codons within a previously functional protein coding sequence causing premature termination of translation of the protein) \[[@CR10]\]. Among all 443-breast cancer patients that were tested in this study with DGGE we detected a large number of *ATM* silent mutations (presumed neutral polymorphisms, data not shown and excluded from all analyses) and missense mutations (causing an amino acid substitution in the coded protein, most common ones; i.e. *D1853N*, not included in further analysis).

ATM missense mutation spectrum {#Sec9}
------------------------------

In our study cohort we have detected 35 distinct *ATM* missense variants and 6 distinct truncating mutations. Several of the detected missense variants have been reported in the ATM database as being detected in A-T patients/or as polymorphisms (Table [1](#Tab1){ref-type="table"}). None of the missense variants identified in this study are known as pathogenic A-T causing missense mutations. Seventeen of the missense variants have not been reported previously. Eleven missense variants were exclusively found in the CBC group and 10 exclusively in the UBC group. Whether this distinction in the spectrum indicates an association between particular variants and bilateral breast cancer risk cannot be concluded from the small numbers obtained in this study population. The *ATM* protein has several functional domains and the identified missense variants are located throughout the ORF. Potential functional implications of the newly identified unclassified variants remain to be established. Table 1*ATM* missense variant and truncating mutation spectrum in contralateral and unilateral breast cancer patientsMissense variantsAmino acid changeCBC *n* = 247UBC *n* = 190Database^a^ or literature37C\>TR13C1\[[@CR10]\]146C\>GS49C55database162T\>CY54H21\[[@CR4]\], \[[@CR14]\]378A\>TD126E1database1009C\>TR337C1Novel1132A\>GS377G1Novel1229T\>GV410A21\[[@CR4]\]1810C\>TP604S1database2119T\>CS707P78database2276G\>AS759NNovel2336T\>CM779T1Novel2414G\>AR805Q2Novel2572T\>CF858L43database2650C\>TP884S12650C\>TP884S1Novel2614C\>TP872S\[[@CR15]\]3161C\>GP1054R813database3925G\>AA1309T11\[[@CR16]\]4138C\>TH1380Y1database4258C\>TL1420F54database4324T\>CY1442H2Novel4362A\>CK1454N1database4477C\>GL1493V1Novel4664T\>AL1555H1Novel4722G\>TL1574F1Novel5044G\>TD1682Y1database5071A\>CS1691R22database*5557G\>A*^b^*D1853N3549*database5558A\>TD1853V31database5741A\>GD1914GNovel6067G\>AG2023R1database6820G\>AA2274T1database6919C\>TL2307F1\[[@CR14]\]7446G\>AM2482I1Novel7874A\>GD2625G1Novel8659C\>GH2887D1NovelTruncating mutationsIVS10-6T\>G419X12database \[[@CR10]\], \[[@CR17]\]1563delAG521X1database1660delA554X1NovelIVS14 + 2T\>Gdel 601-6331database2572insTF858X1Novel3115A\>TR1039X1Novel^a ^<http://chromium.liacs.nk/lovd/>^b ^Not included in frequency analysis

Despite the fact that *ATM* plays a role in breast cancer risk, the role of most distinct *ATM* missense variants remains unclear. Some studies tried to predict the relevance of each particular mutation on basis of co-segregation with breast cancer in families, the location in a functional domain or interference with the splicing machinery. Only a few studies present functional analysis that are necessary to assess the biological impact of unidentified variants found frequently in *ATM* \[[@CR18]--[@CR20]\].

ATM missense mutations and contralateral breast cancer {#Sec10}
------------------------------------------------------

Twenty-one per cent of the patients carried at least one *ATM* germline variant (missense and truncating; Table [2](#Tab2){ref-type="table"}). Among the patients with CBC (*n* = 247) we identified in total 55 *ATM* variants in 45 individuals (18%); 51 missense variants and 4 truncating mutations (Table [2](#Tab2){ref-type="table"}). Eight CBC patients had multiple *ATM* missense variants and 2 patients carried both a missense and a truncating *ATM* mutation. In the women with UBC (*n* = 196) we identified 52 *ATM* variants in 46 individuals (23%); 48 missense and 4 truncating mutations. Three UBC patients carried double missense and 3 patients both a truncating and a missense variant. Although it is known from the literature that *ATM* missense variants might be involved in breast cancer pathogenesis, the identified 17% missense variant carriers among the CBC patients compared to the 21% missense variants among the UBC patients indicate that there is not a significantly increased risk for bilateral breast cancer among *ATM* missense variant carriers, OR 0.77 (95% CI 0.48--1.24). Table 2*ATM* variant frequencies in all breast cancer patients diagnosed under age 50 and according to uni- or contralateral breast cancerBreast cancer patients withAll patients *n* = 443CBC *n* = 247UBC *n* = 196Total *ATM* variants^a^55: 51 missense and 4 truncating52: 48 missense and 4 truncatingAt least one *ATM* variant91 (21%)45 (18%)46 (23%)At least one *ATM* missense variant85 (19%)43 (17%)42 (21%)Only one *ATM* truncating mutations321One truncating and one missense variant523Double missense variants1183^a ^Not included are the most common and silent variants

Association with radiation treatment {#Sec11}
------------------------------------

Women at high risk for developing breast cancer may respond differently to radiation exposures associated with screening and treatment, than the general population. Candidate-genes like *ATM* are implicated in maintenance of genome integrity. Their involvements in breast cancer susceptibility as well as their role in DNA-damage repair signalling make them excellent candidates for a role in radiation-induced breast cancer \[[@CR21]\]. Recently, we showed that women with a pathogenic germline mutation in a DNA repair pathway gene (e.g. *BRCA1, BRCA2, CHEK2* and *ATM*) have an over 2-fold increased risk of developing radiation-associated breast cancer (manuscript under review). Therefore, we now investigated whether exposure to ionising radiation had a greater biological impact on certain *ATM* genotypes than on others.

We did not detect a significantly increased risk of developing radiation-associated CBC among missense mutation carriers. Among those 169 CBC patients who had developed a second primary breast tumour following radiotherapy for their first breast tumour we identified 19.5% *ATM* missense variants carriers compared to 13% among those CBC patients who did not receive RT, the OR from this case-only analysis is 1.65 \[95% CI (0.77--3.55) *p* = 0.2\]. Furthermore, we have observed that 21% of the UBC patients, who received RT but did not develop a CBC carried an *ATM* missense variant, compared to 19.5% of the CBC patients that received RT for their first tumour \[OR 0.86 (95% CI 0.52--1.43)\]. These results suggest that RT is not a strong risk factor for the development of CBC among carriers of those ATM missense variants.

It has however been shown that particular alterations in the *ATM* gene are associated with increased radiation sensitivity \[[@CR22]--[@CR24]\]. Gutierrez-Enriquez et al. showed that lymfoblastoid cell lines carrying the *ATM* variant 3161G (linked to 2572C) was associated with increased in vitro chromosomal radio-sensitivity, perhaps by interfering with *ATM* function in a dominant-negative manner \[[@CR22]\]. We found this particular variant allele (3161G/2572C) exclusively in our CBC group exposed to radiotherapy (four times) and not in the non-RT-exposed CBC group. This finding supports the hypothesis that particular *ATM* variants might play a differential role in radiation response. Although a subset of the missense variants was only detected in the RT exposed subpopulation, individual numbers were probably too small to detect a significant effect of particular mutations associated with treatment.

We observed that CBC patients with an *ATM* missense variant had an mean interval between the first and second breast tumour of ∼101 months, compared to 122 months for non-carriers CBC patients (*p* = 0.085). Interestingly, the combination of radiation treatment and a missense variant resulted in an even shorter mean interval of a 92 months in the CBC patients compared to a 136-month interval for CBC patients who neither received RT nor carried a germline variant (*p* = 0.029). These data suggest that carrier-ship of an ATM missense variant may accelerate the development of a second tumour and decreases the age at onset of the second breast tumour, especially in case of exposure to RT.

The suggestion of a shorter induction period of RT-associated breast cancer in patients, who carry an ATM missense mutation, while the proportion of patients with missense variants was similar in CBC and UBC cases, might be attributable to a different spectrum of mutations in those patients who developed CBC. A big challenge in such a study remains to assess which particular missense mutations have an impact on ATM function. Large association studies, as performed by the Breast Cancer Association Consortium (coordinated by Doug Easton and Paul Pharoah, Cambridge), and functional studies are clearly necessary to determine the importance of particular variants and their contribution to the breast cancer risk.
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